Determine the necessary mass, volume, or concentration for preparing a solution.
10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Pentagamavunon-1 (PGV-1), a Curcumin analog with oral activity, targets on several molecular mechanisms to induce apoptosis including inhibition of angiogenic factors cyclooxygenase-2 ( COX-2 ) and vascular endothelial growth factor ( VEGF ). PGV-1 inhibits NF-κB activation.
In Vitro
Pentagamavunon-1 (PGV-1, 1, 2.5, 5, 7.5, 10, 15, and 20 µM) enhances cytotoxic effect of 5-FU on WiDr cells. Pentagamavunon-1 (PGV-1, 1, 2.5, 5, and 10 µM) shows different effects on cell cycle progression and induces G2/M arrest. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay. Cell Line: Human colon carcinoma WiDr. Concentration: 1, 2.5, 5, 7.5, 10, 15, and 20 µM. Incubation Time: 6, 12, 24, and 48 hours. Result: Significantly enhanced the cytotoxicity of 5-FU on WiDr cells at various concentrations during 6, 12, 24, and 48 h incubation. Cell Cycle Analysis. Cell Line: WiDr cells. Concentration: 1, 2.5, 5, and 10 µM. Incubation Time: 24 h. Result: The non-treated WiDr cells showed cell accumulation in G1, S, and G2/M phase about 50.85%, 36.11% and 13.04%, respectively.
In Vivo
Pentagamavunon-1 (PGV-1, po, 20 mg/kg) exhibits significant anti-tumor activity in PDX model, without obvious toxicity . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Human cancer cells in a xenograf mouse model. Dosage: 20mg/kg. Administration: P.O. every 2 days for 20 days. Result: Exhibited little decrease in body weight, nor a decrease in white and red blood cell counts in peripheral blood, nor any other efects in behavior and macroscopic appearance. Thus,\nPGV-1 was sufciently potent to suppress tumor formation in vivo, but exhibited little or no obvious adverse effects on the normal lineage of cells.
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →